Publications Press Releases. Clinical Trial Registry. InnoCare may register the Clinical Study with the Clinical Trials Registry located at xxx.xxxxxxxxxxxxxx.xxx and xxx.xxx.xxx.xx in accordance with Applicable Law.
Publications Press Releases. Unless otherwise mutually agreed by the Parties, no Party shall have the right to publish or allow the publishing of any Foreground Information, Background Information, or Confidential Information of the other Party(ies), even where such Information is amalgamated with such Party’s Foreground Information, Background Information, or other Information. A copy of any proposed publication or communication including or in connection with Foreground Information, Background Information, or Confidential Information of the other Party, shall be sent to the IP Committee at the earliest time possible and no fewer than sixty (60) days prior to such proposed publication or communication. The IP Committee may object to the publication within twenty five (25) calendar days after receipt of a copy of the proposed publication. The proposed publication shall not take place until the expiration of the above-identified period of twenty five (25) calendar days. In the event that an objection is raised on any of the grounds defined above within the above-identified period of twenty five (25) calendar) days, the Party proposing the publication and the IP Committee objecting shall seek in good faith to agree on a solution on a timely basis whereby such objection is resolved. Such publication shall not be made without the Parties’ express approval based on the advice of IP Committee. In the absence of any express approval within the above-mentioned period, it is deemed that the Parties disagree to the proposed publication. The Parties hereby agree that any Party may issue a press release upon execution of this Agreement, attached hereto as Exhibit J. Each party approves the press release in Exhibit J for issuance as is without further approval or consent and the filing of a Form 8-K with the United States Securities and Exchange Commission fully consistent with the press release in Exhibit J. The parties shall mutually agree upon in writing (i) any other public disclosure that a Party may have to make in connection with the signing of this Agreement to comply with applicable Law, including the filing of a Form 8-K with the United States Securities and Exchange Commission, or (ii) any public disclosure in connection with this Agreement, Project 1, or any R&D Activity that either Party or the Parties may decide to make.
Publications Press Releases. (a) TPT will register the Combined Therapy Clinical Trial on xxx.xxxxxxxxxxxxxx.xxx or any other public database or registry as required by Applicable Law. TPT will use Commercially Reasonable Efforts to submit the results of the Combined Therapy Clinical Trial for publication within [***] months after completion of the Combined Therapy Clinical Trial, after taking appropriate action to secure intellectual property rights (if any) arising from the Combined Therapy Clinical Trial after taking EQRx’s input into consideration in good faith in accordance with the terms and conditions of Article 5, and subject to EQRx’s prior review of any such publications as set forth in paragraph (b) of this Section 7.4. TPT and EQRx agree to collaborate reasonably and in good faith to publicly disclose, publish or present top-line (interim or final) results and data from the Combined Therapy Clinical Trial, limited, if possible to avoid jeopardizing the future publication of the Combined Therapy Study Data at a scientific conference or in a scientific journal, solely for the purpose of disclosing, as soon as reasonably practicable, the safety or efficacy results and conclusions that are material to either Party under applicable securities laws. EQRx agrees not to publish or otherwise publicly disclose the results of the Combined Therapy Clinical Trial prior to the earlier of (i) publication of the Combined Therapy Clinical Trial results by TPT or (ii) [***] months after completion of the Combined Therapy Clinical Trial. Each Party’s publications will be developed in accordance with accepted scientific practice and its respective internal policies and practices.
(b) Unless otherwise mutually agreed upon by the Parties, (i) the Party desiring to publish or present any publication or presentation concerning the activities to be conducted hereunder (the “Publishing Party”) will transmit to the other Party (the “Reviewing Party”) for review and comment (A) a copy of a proposed abstract at least [***] days prior to the proposed submission to a Third Party, or (B) a copy of any other proposed publication or presentation at least [***] days prior to the proposed submission of the publication or presentation to a Third Party; (ii) the Publishing Party will postpone the publication or presentation for [***] days (or longer, if mutually agreed upon by the Parties) upon request by the Reviewing Party in order to allow the consideration of appropriate patent applications or other protec...
Publications Press Releases. 12.1. Clinical Trial Registry. Company shall register the Study with the Clinical Trials Registry located at wxx.xxxxxxxxxxxxxx.xxx and is committed to timely publication of the results following Study Completion, after taking appropriate action to secure intellectual property rights (if any) arising from the Study. The publication of the results of the Study will be in accordance with the Protocol.
Publications Press Releases. Except as required by law or court order, all publicity, press releases and other announcements or disclosures, including, without limitation, any publications and/or presentations in any scientific journal, professional conference and commercial fairs, relating to the existence and terms of this Agreement or the transactions contemplated hereby, including, without limitation, any data collected during the pre-clinical and Phase I clinical trials conducted in the course of the Project and the results of such trials, shall be reviewed in advance by, and shall be subject to the written approval of, both parties; provided that such publicity, press releases and other announcements shall not disclose any confidential information of the other party hereunder and shall give appropriate attribution to the other party’s role(s) in the project contemplated herein. Without derogating from the foregoing, each party shall provide the other party an opportunity to review and comment on the language of such attribution prior to first use thereof in a press release or other public disclosure. Either party may disclose the existence of this Agreement and the terms and conditions hereof, without the prior written consent of the other party, as may be required by applicable law (including, without limitation, disclosure requirements of the SEC, NYSE, or any other stock exchange or NASDAQ), in which case the party seeking to disclose the information shall give the other party reasonable advance notice and review of any such disclosure and shall seek confidential treatment of such information to the extent possible under applicable law. [*****] Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission.
Publications Press Releases
